Now Reading: Thalia Therapeutics Advances Clinical Pipeline with Sanmirna Acquisition and Oversubscribed Fundraise
-
01
Thalia Therapeutics Advances Clinical Pipeline with Sanmirna Acquisition and Oversubscribed Fundraise
Thalia Therapeutics Advances Clinical Pipeline with Sanmirna Acquisition and Oversubscribed Fundraise
Thalia Therapeutics plc (AIM:THAT), the AIM-listed RNA therapeutics developer, has confirmed that its proposed acquisition of Sanmirna Therapeutics and an oversubscribed £2.75 million fundraising represent a transformational milestone for the company. Shareholders are scheduled to vote on the transaction at the annual general meeting taking place on Friday morning in London.
Chief executive Dr David Solomon outlined to investors that the transaction would accelerate Thalia’s progression into a clinical-stage biotechnology enterprise whilst substantially enhancing its RNA therapeutics pipeline. Subject to shareholder approval at the AGM, the acquisition will introduce miRisten to Thalia’s portfolio, a Phase 1 clinical-stage microRNA therapeutic targeting acute myeloid leukaemia.
The addition of miRisten will complement the company’s existing proprietary Nuvec delivery technology and its dual-targeting cardiovascular siRNA programme. Dr Solomon characterised the resulting portfolio as diversified, addressing multi-billion-dollar global markets in both oncology and cardiovascular disease.
Topline data from the Phase 1 miRisten study are anticipated during the first half of 2027, ahead of preparations for Phase 2 trials. The clinical trial remains active, although patient enrolment has been temporarily paused to allow the current cohort to progress through the study protocol.
Dr Solomon confirmed that funding has been secured for planned work across the portfolio, including completion of the miRisten trial. The company’s immediate priorities following completion of the acquisition include integrating Sanmirna’s operations, advancing the cardiovascular programme towards IND-enabling studies, and continuing development of Nuvec as a differentiated RNA delivery platform.
The chief executive stated that Thalia is entering an exciting new phase of development, with the board focused on delivering several important value-creating milestones in the coming months.
Post Disclaimer
The following content has been published by Stockmark.IT. All information utilised in the creation of this communication has been gathered from publicly available sources that we consider reliable. Nevertheless, we cannot guarantee the accuracy or completeness of this communication.
This communication is intended solely for informational purposes and should not be construed as an offer, recommendation, solicitation, inducement, or invitation by or on behalf of the Company or any affiliates to engage in any investment activities. The opinions and views expressed by the authors are their own and do not necessarily reflect those of the Company, its affiliates, or any other third party.
The services and products mentioned in this communication may not be suitable for all recipients, by continuing to read this website and its content you agree to the terms of this disclaimer.
Related Posts
